Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin plus CHP as first-line treatment for CD30-positive peripheral T-cell lymphoma in Chinese patients
CTR20223016Phase 2Active
- Sponsor
- Takeda
- Start
- Feb 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone in peripheral T-cell lymphoma (PTCL), sponsored by Takeda. Started Feb 2023; status: active.
02
Drugs
brentuximab vedotincyclophosphamidedoxorubicinprednisone
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20223016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223016.